Vildagliptin+ Metformin HCL
The combination of Vildagliptin and Metformin HCL is used for the effective management of type 2 diabetes mellitus. Vildagliptin is a DPP-4 inhibitor that increases insulin secretion and decreases glucagon secretion in response to meals, while Metformin is a biguanide that reduces hepatic glucose production and enhances insulin sensitivity. Together, they provide improved glycemic control.
- Recommended Usage
Indications:
- Management of type 2 diabetes mellitus in adults.
- As an adjunct to diet and exercise to achieve better glycemic control.
- Suitable for patients not adequately controlled on Metformin alone or as initial therapy in patients with inadequate control on lifestyle modifications.
Dosage & Administration:
- Administered orally, typically twice daily with meals to reduce gastrointestinal side effects.
- Common doses: Vildagliptin 50mg + Metformin 500mg/850mg/1000mg.
- Maximum daily dose: Vildagliptin 100mg and Metformin 2000mg.
- Adjust dosage based on glycemic response and renal function.
Precautions:
- Contraindicated in patients with severe renal impairment, metabolic acidosis, or known hypersensitivity to any component.
- Use cautiously in patients with hepatic impairment or cardiovascular disease.
- Monitor renal function and blood glucose levels regularly.
- Discontinue immediately if signs of lactic acidosis or pancreatitis occur.
Key Benefits:
- Dual Action: Combines two complementary mechanisms to enhance glycemic control.
- Postprandial Glucose Control: Effectively reduces post-meal blood glucose levels.
- Low Risk of Hypoglycemia: Minimal risk when used as directed.
- Improved Adherence: Simplifies treatment by combining two medications in one.
